Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brent McHenry

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Gastrointestinal Cancer Research : GCR|November 1, 2012
A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancerCaio M Rocha Lima, Edward H Lin, George P Kim, et al.
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Gastrointestinal Cancer Research : GCR|November 1, 2012
A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancerCaio M Rocha Lima, Edward H Lin, George P Kim, et al.
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Pageof 3